It's time to start living." Emily S******** "I'm no longer insecure about getting undressed in front of my husband" Tess B******* "I was initially nervous about injections, but it was painless
Study: Glucagon-like peptide-1 receptor agonists and muscle mass effects
This type of optimization turns scattered free moments into satisfying, bite-sized sessions without lengthy waiting or disorienting lag
Semaglutide (Wegovy) is FDA-approved for chronic weight management (with criteria) and has strong clinical trial evidence for meaningful average weight loss when paired with lifestyle support
Our goal is to help you build a routine that works for your performance and your long-term wellness
TRANSCEND-T2D-1 (NCT06354660), the program's first trial, reported topline results March 19, 2026, with full publication in The Lancet in June